Congenital toxoplasmosis: Prevention or palliation?

American Journal of Obstetrics and Gynecology

Volumn 141, Issue 4, 1981, Pages 359-361

  Frenkel, J K ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; PYRIMETHAMINE; SULFADIAZINE;

ANIMAL EXPERIMENT; CONGENITAL TOXOPLASMOSIS; DRUG THERAPY; EDITORIAL; EDUCATION; EMBRYO; FETUS; HYGIENE; PALLIATIVE THERAPY; PREGNANCY; PREVENTION; PROTOZOON; SEROLOGY; THERAPY; TOXOPLASMA;

ADOLESCENT; ADULT; FEMALE; HEALTH EDUCATION; HUMAN; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRIMARY PREVENTION; SUPPORT, U.S. GOV'T, P.H.S.; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL; UNITED STATES;

EID: 0019444453     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9378(81)90595-0     Document Type: Article

References (5)

1. What can be done to prevent congenital toxoplasmosis?
2. Toxoplasma in and around us
3. Congenital toxoplasmosis
4. Toxoplasmosis. Mechanisms of infection, laboratory diagnosis and management
5. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection